Full Breakdown
Vitamin B3 Shows Promise for Treating NAXD Deficiency
2/26/2026, 1:01:06 PM
Innovative Approach to Treatment Discovery
Researchers at Gladstone Institutes have pioneered a novel method for identifying potential treatments for genetic diseases by starting with vitamins rather than the diseases themselves. This approach led to the discovery that high-dose vitamin B3 supplementation can effectively treat NAXD deficiency, a rare genetic disorder that typically results in death within the first few months of life. In a mouse model of the condition, vitamin B3 therapy extended the lifespan of affected mice by more than 40 times and eliminated disease symptoms. Isha Jain, PhD, a senior author of the study published in *Cell*, emphasized the goal of using modern genetics to systematically identify which diseases can be treated with specific vitamins.
Mechanism of Action
The research team utilized CRISPR gene editing to remove specific genes from human cells, testing their survival under high levels of vitamins. They found that cells lacking the NAXD gene survived better in high-vitamin conditions. NAXD deficiency leads to the accumulation of damaged NADH, an essential energy-carrying molecule, causing severe developmental issues. The study demonstrated that administering high-dose vitamin B3 to a newly developed mouse model of NAXD deficiency resulted in significant improvements. Treated mice, which initially appeared normal, survived well beyond the typical lifespan of untreated mice, with normalized levels of NADH and serine, and no signs of brain inflammation.
Implications for Early Diagnosis and Treatment
The findings suggest that early diagnosis and treatment are crucial for managing NAXD deficiency. Jain advocates for the inclusion of NAXD in newborn screening panels, stating that immediate therapy could save lives. While previous anecdotal evidence indicated that some patients improved with vitamin supplements, this study provides experimental validation of vitamin B3’s potential to address the underlying causes of the disease.
Broader Applications and Future Research
The framework developed by Jain's team not only holds promise for NAXD deficiency but also identifies numerous other genetic conditions that may respond to vitamin therapies. Jain expressed optimism about the potential to discover vitamin treatments for hundreds of genetic diseases, encouraging other laboratories to apply this framework to explore the therapeutic effects of various micronutrients beyond vitamins.
Official Statements & Responses
Jain remarked, "This tells us that NAXD should be added to newborn screening panels. If we can diagnose children immediately after birth and start therapy, we may be able to save lives." Co-first author Ankur Garg, PhD, noted, "Our screen suggested that something as simple as giving vitamin B3 could make a difference for human patients."
Verbatim Quotes
- “Our goal is to revisit classical vitamin biology with causal and rigorous frameworks,” — Isha Jain, PhD, Gladstone Investigator
- “The treated mice were indistinguishable from their healthy littermates,” — Skyler Blume, Research Associate
- “We could potentially identify vitamin therapies for hundreds of genetic diseases.” — Isha Jain, PhD, Gladstone Investigator
This research not only highlights the potential of vitamin B3 in treating NAXD deficiency but also opens avenues for future studies on vitamin therapies for other genetic disorders.
